FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma By Ogkologos - August 8, 2025 742 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LINKER-MM1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR ESMO Asia Congress 2022, 2-4 December 2022 November 17, 2022 New Study Finds Dogs Can Sniff Out Lung Cancer — And... April 10, 2019 FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... October 10, 2025 Significant Intracranial Efficacy and Survival Benefits of Osimertinib in Patients with... July 25, 2024 Load more HOT NEWS Metastatic Breast Cancer: New ESMO Guideline With Evidence-Based Recommendations [ESMO Press... Responding to Coronavirus, Cancer Researchers Reimagine Clinical Trials Breast Cancer Patient Fights To Have Mastectomy During COVID-19 Restrictions And... Curbing Production of Immune Checkpoint Protein Slows Liver Cancer in Mice
